Treatment of solid tumors and lymphomas with methyl-CCNU (NSC-95441): a phase II study.
Explore the source record for details and available documents.
Adult↗
Biomedical subjects
G Tekuzman
Publications and source records attributed to G Tekuzman.
Solitary phalanx plasmacytoma relapse with disseminated extramedullary plasmacytomas and myeloma after short duration of remission.
Solitary bone plasmacytomas account for 5-7% of multiple myeloma cases and are assumed to have a fairly good prognosis, with a long duration of relapse-free survival after primary local treatment. Isolated phalanx plasmacytoma is a very rare entity, because involvement of extremities is seen in less than 1% of all solitary bone plasmacytomas, where they are usually localized centripedally, often in the axial skeleton. A 68 year old patient with a lytic lesion involving 5th phalanx was diagnosed as having a biopsy-proven solitary plasmacytoma, with a negative work-up for coexisting plasma cell dyscrasia. Three and a half months after completion of radiotherapy of the involved phalanx, the patient was readmitted with hypercalcemia, renal insufficiency and subsequently diagnosed as having atypical plasma cell infiltration of marrow, and plasmacytomas involving the right vocal cord and the premaxillary region, as well as pathological ulna fracture. Plasmacytoma of the phalanx, with extreme short duration of remission and an aggressive type of clinical relapse, is in sharp contrast with the natural stable course of a solitary plasmacytoma where the use of systemic treatment is subject to intense debate.
Aged↗
Procarbazine, CCNU, vincristine combination in the treatment of brain tumors.
Forty patients with primary malignant brain tumor were treated by combination chemotherapy after prior treatment with surgery and radiotherapy. The chemotherapy schedule consisted of PCV: procarbazine per os, 100 mg/m2, during 14 consecutive days; CCNU, per os, 80 mg/m2 on day 1 and vincristine, intravenously, 1.4 mg/m2 on days 1 and 14. This protocol was planned to be repeated every 45 days for 6 courses. Median 5 courses (range, 2-6) of chemotherapy was administered to patients. The median relapse free (RFS) and overall survival (OS) rates were found to be 28 and 79+ months, respectively. According to univariate analysis, performance status (PS) of patients was an important prognostic factor on RFS and OS where extent of surgery was an additional significant determinant of OS. Multivariate analysis of pretreatment factors revealed the influence of sex, type of histopathology and PS on RFS and that of PS on OS rates (P < 0.05). The toxicity of this regimen was mild to moderate. The major toxicity noted was myelosuppression. Severe (grade III-IV) neutropenia and thrombocytopenia has been observed in 13 (7%) and 6 courses (3.5%), respectively. In general, PCV is well tolerated and the median RFS and OS times elucidated are comparable with particular trials utilizing combination chemotherapy and longer than using radiotherapy alone.
Adolescent↗
A questionnaire for the assessment of quality of life in cancer patients in Turkey.
In this study, we developed a reliable scale to measure the quality of life (QOL), which would reflect the cultural characteristics of cancer patients in Turkey. We used the Rolls-Royce model and determined a form with 49 items in eight dimensions such as general well-being, physical symptoms and activity, sleep dysfunctions, appetite, sexual dysfunction, cognitive functions, medical interaction, social participation and work performance. The forms were used for assembling data from 100 subjects (10 physicians, 19 healthy volunteers, 18 patients relatives, 28 patients on chemotherapy, 25 patients off chemotherapy). Half-split reliability and the signal effect were used to demonstrate reliability and responsiveness. After demonstrating the validity of the test, the final form was constructed. When these eight dimensions were factor analysed, it was found that the general well-being and sexual dysfunction were the most important determinants of QOL.
Adolescent↗